Evidence mapPaperPMID 37110230Full record

ArticleMetabolites2023

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration.

Victor Enrique Sarmiento-Ortega, Diana Moroni-González, Alfonso Diaz, Miguel Ángel García-González, Eduardo Brambila, Samuel Treviño

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Victor Enrique Sarmiento-OrtegaLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Meritorious Autonomous University of Puebla, 14 Sur. FCQ1, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0002-7940-6059
Diana Moroni-GonzálezLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Meritorious Autonomous University of Puebla, 14 Sur. FCQ1, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0003-4500-0648
Alfonso DiazDepartment of Pharmacy, Faculty of Chemistry Science, Meritorious Autonomous University of Puebla, 22 South, FCQ9, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0003-4092-6636
Miguel Ángel García-GonzálezLaboratory of Clinical Pharmacy, Faculty of Chemistry Science, Meritorious Autonomous University of Puebla, 22 South, FCQ10, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0002-0826-2932
Eduardo BrambilaLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Meritorious Autonomous University of Puebla, 14 Sur. FCQ1, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0003-0377-0943
Samuel TreviñoLaboratory of Chemical-Clinical Investigations, Department of Clinical Chemistry, Meritorious Autonomous University of Puebla, 14 Sur. FCQ1, Ciudad Universitaria, Puebla City 72560, Mexico.ORCID 0000-0001-5679-1671
Benemérita Universidad Autónoma de Puebla · MX

Funding

CONACyT 658590
6 · The paper itself

Abstract

Metabolic diseases are a worldwide health problem. Insulin resistance (IR) is their distinctive hallmark. For their study, animal models that provide reliable information are necessary, permitting the analysis of the cluster of abnormalities that conform to it, its progression, and time-dependent molecular modifications. We aimed to develop an IR model by exogenous insulin administration. The effective dose of insulin glargine to generate hyperinsulinemia but without hypoglycemia was established. Then, two groups (control and insulin) of male Wistar rats of 100 g weight were formed. The selected dose (4 U/kg) was administered for 15, 30, 45, and 60 days. Zoometry, a glucose tolerance test, insulin response, IR, and the serum lipid profile were assessed. We evaluated insulin signaling, glycogenesis and lipogenesis, redox balance, and inflammation in the liver. Results showed an impairment of glucose tolerance, dyslipidemia, hyperinsulinemia, and peripheral and time-dependent selective IR. At the hepatic level, insulin signaling was impaired, resulting in reduced hepatic glycogen levels and triglyceride accumulation, an increase in the ROS level with MAPK-ERK1/2 response, and mild pro-oxidative microenvironmental sustained by MT, GSH, and GR activity. Hepatic IR coincides with additions in MAPK-p38, NF-κB, and zoometric changes. In conclusion, daily insulin glargine administration generated a progressive IR model. At the hepatic level, the IR was combined with oxidative conditions but without inflammation.

Indexed as

dyslipidemiainflammationinsulin resistanceinsulin signalingoxidative stress

Identifiers

PMID37110230
PMCPMC10144445
OpenAlexW4366348144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.